The pharmaceutical union of 2,500 people has been launched

The NPU to conduct launch ceremony on 5th

The first chairman is Ahn Deok-hwan, head of the Korea Novartis union.

 

Fifteen multinational companies and one domestic company participated in the NPU launch ceremony after three years of discussion

"Working conditions are deteriorating despite increased sales in the pharmaceutical industry.

 

Active response to common issues" The nation's largest pharmaceutical labor union has been newly created.

 

The new labor union, which consists of a total of 2,500 pharmaceutical workers, expressed its willingness to jointly respond to the pharmaceutical company's restructuring moves.

 

The NPU held a launching ceremony at the FKTU on the morning of the 5th.

 

Kim Dong-myung, chairman of the FKTU, Hwang In-seok, chairman of the FKTU, Kim Ki-chul, chairman of FKTU's Seoul regional headquarters, Nam Sung-hee, chairman of FKCU's pharmaceutical cosmetics division, and Yoo Byung-jae, CEO of Novartis Korea, attended the meeting.

 

A total of 16 domestic and foreign pharmaceutical labor unions, including ▲Novonodisc Pharmaceutical, ▲Bayer Korea, ▲Amgen Korea, ▲Ipsen Korea, ▲Novatis Korea, ▲Viatris Korea, ▲ Janssen Korea, ▲ Pfizer Pharmaceutical, ▲ Sanofi Aventis Korea, ▲Alvogen Korea, ▲Opella Healthcare Korea, ▲Merck, ▲Beringer Ingelheim, ▲AstraZeneca, ▲GSK, and ▲Hyundai Pharmaceutical.

 

Eight unions, including Novonodisc Pharmaceutical and Pfizer Pharmaceutical Korea, have already decided to switch to industrial unions.

 

Eight unions, including the AstraZeneca Korea Union, are preparing to switch industries.

 

The total number of union members was about 2,500.

 

Those who have been preparing for a new union of pharmaceutical unions for about two years since 2019 formed an integrated promotion committee for some unions and non-affiliated unions that left the KDPU, and officially established the NPU last year.

 

In a declaration of launch, Ahn Deok-hwan, the first chairman of Novartis Korea, said, "The Korean pharmaceutical industry is suffering from job insecurity and a real decrease in wage income through the fourth revolution and COVID-19." "I felt the need for solidarity as I recognized these problems as the same problems that appeared in the pharmaceutical industry as a whole, not in a specific company," he said.

 

He then stressed, "The NPU will firmly maintain employment stability, raise wages and welfare, and respond intensively to common problems arising from low growth and non-face-to-face operations in the name of voluntary retirement." Yoo Byung-jae, CEO of pharmaceutical industry, said in a congratulatory speech, "Congratulations on the launch of NPU.

 

The pharmaceutical bio industry is facing a reorganization of its organizational structure to improve innovation and productivity, he said.

 

"I think trust between employees and companies is more important than anything else for companies to grow continuously and stably." There may be conflicts of interest between each subject, but we hope to establish a constructive relationship with the NPU," he said.

 

The NPU is closely watching the reduction of personnel due to the recent reorganization at the global level.

 

For example, Pfizer, which is in the process of reorganizing its sales department, is likely to implement additional Voluntary Early Retirement Programs.

 

In addition, Novartis recently announced plans to reduce the number of people worldwide by integrating the organization at a global level.

 

In addition to the overlapping number of people due to department integration, additional personnel reduction can be made in Korea.

 

Chairman Ahn said, "The Voluntary Early Retirement Programs have been doing ERP due to a lack of trust that the union can protect itself, even though the subject has to be a worker.

 

The NPU will try to gain confidence in its members that it can protect them."